Medicine Recommendations

Treating moderate to severe plaque psoriasis (NICE TA511)

NICE TA511 - Brodalumab for treating moderate to severe plaque psoriasis

Brolucizumab for treating wet age-related macular degeneration (TA672)

Treating diabetic macular oedema - NICE TA820

NICE TA820 - Brolucizumab for treating diabetic macular oedema

Parkinson's disease

MHRA Drug Safety Update - Ergot-derived dopamine agonists: risk of fibrotic reactions

Treating primary IgA nephropathy (NICE TA937)

NICE TA937 - Targeted-release budesonide for treating primary IgA nephropathy

For induction of remission in adults with mild to moderate active ulcerative colitis where 5-ASA (aminosalicylate) treatment is not sufficient.

Induction of remission in patients with active microscopic colitis (MC).

For inducing remission of eosinophilic oesophagitis. 

NICE TA 708 - Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis

Refer to LSCMMG COPD Guidelines (link below)

Pain.

Only for use in patients who are unable to take or tolerate oral medicine (including soluble tablets and liquids) OR where use of the low-dose buprenorphine patches may prevent administration problems for frail, elderly patients in the community.

Pain, in patients who are unable to take or tolerate oral medicine, (including soluble tablets and liquids).

Anxiety (short term use)

Severe intractable insomnia only in patients already taking barbiturates

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration

Hyperprolactinaemia

Parkinson's disease

MHRA Drug Safety Update - Ergot-derived dopamine agonists: risk of fibrotic reactions

Psoriasis

Hypercalcaemia

Prevention of sudden bone loss due to sudden immobility

Hyperphosphataemia associated with renal failure

Phosphate binder - Renal Dialysis

Following a Gastric Bypass